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CHAPTER 1. ABOUT THE INVESTIGATION
1.1 SIGNIFICANCE OF THE INVESTIGATION
Cysteine proteases of the 13- membered calpain and papain family (CA clan) play a
significant role in the maintenance of normal cellular function and structure.1-4 They are essential
to the hydrolytic behavior of lysosomes and allow healthy cells to thrive and regenerate. They are
known for their unique active site properties and uneven, tissue-specific expression patterns. Of
these, cathepsins K, B and S are extremely critical as they are directly involved in osteoclastic
bone resorption and macrophage invasion. The downfall of this highly instrumental system is the
effects of its malfunction. When CA protease are imbalanced or mislocalized, they contribute
instead to the destruction of normal function and structure; they play an active role in the
progression of many diseases including osteoporosis, atherosclerosis, lung, breast and prostate
cancer and many other systemic diseases. For this reason, they are of high medical importance.
Cathepsin K (CST-K) is important to bone remodeling and function.2 The major
consequence of upregulated and mislocalized CST-K is the progression of osteoporosis, and bone
metastases of lung, breast, and prostate cancers. It is more highly expressed in bone marrow
macrophages, and stromal cells in the metastatic environment than that of the primary tumor, this
makes metastatic bone cells an optimal target for tumor reduction. Related studies found that the
growth and progression of intratibially implanted prostate carcinoma cells (PC3) were significantly
reduced in cathepsin K knockout mice versus wild type mice,5 thus verifying its importance.
Cancer has been defined as a malignant tumor that results from an uncontrolled division of
genetically-mutated cells.6 It is a disease, claiming over 17,000 lives daily worldwide,7 and as such
it is the main focus of numerous research teams and pharmaceutical companies.1, 8-13 Currently,
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there are numerous clinically developed strategies being employed to combat all the 100+ cancer
types. These include surgery, immunotherapy, laser therapy, stem cell transplant, hyperthermia,
photodynamic therapy (PDT) and blood transfusion. However, two of the most common
treatments are orally administered chemotherapy and radiation therapy. Oral treatments lack the
ability to achieve location-specific inhibition.11 The lipophilic character of these therapeutics
increases cell permeability, but cell accumulation and anti-target inhibition occur once they are
ionized and trapped inside the cell due to the high homology of the CA proteases. This leads to
poor therapeutic efficacy, dose escalation, drug resistance and intensified side effects. Radiation
therapy uses high doses of radiation to kill cancer cells, but produces side effects such as hair loss,
nausea and motion sickness.14
It is therefore necessary to minimize these risks and costs effects through optimizing drug
exposure in future therapies. As scientists probe the current methodologies, new technologies are
invented.10,

12, 15-21

One such strategy, is photo-activated chemotherapy (PACT).22-23 In this

method, a drug is caged‡ to a chaperone§ allowing spatial and temporal control over drug delivery
at the infected site. The localization of abnormal proteolysis by CST-K, makes it a prime target for
PACT.
The study reported here describes the investigation of a PACT RuII complex that can be
used to permit spatio-temporal control and optimize drug release and exposure for protein
inhibition. This strategy has been under development in this research team for approximately 5
years though the pharmacological interest toward cancer treatment has always been central. In the
past, inhibitors were bound to the chaperone via a ruthenium-nitrile (RuII–N≡CR) dative bond.

‡
§

Attached by a dative or covalent bond
A RuII complex, organic protecting group, nanoparticle, or vesicle that can be separated from a drug by photolysis
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However, as a result of the instability of these complexes in growth media, a new binding
arrangement was sought that will produce similar or better dissociative quantum yields, dark/light
IC50 ratios (DLIR)**, binding affinities and stabilities in growth media. In this study, derivatives
of known cysteine protease inhibitors are synthesized and analyzed for inhibition against
recombinant human cathepsin K. The most potent derivative is then complexed to a [Ru II]††
chaperone by a pyridyl substituent and analyzed in the absence and presence of light. Light permits
the photo-activation of the [RuII-inhibitor], allowing the release of the CST-K inhibitor.

**
††

DLIR = IC50 (pre-irradiation) ÷ IC50 (post-irradiation)
[ ] = complex; exempli gratia: [RuII] = RuII complex
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1.2 OVERVIEW OF THE INVESTIGATION
The main goal of this project was to investigate the effect of a new [RuII]-inhibitor binding
arrangement on CST-K inhibition, id est, [RuII]-N≡CR binding versus [RuII]-pyR. To do this, we
incorporated an N-heteroatom in a known CST-K inhibitor, by exchanging the phenyl substituents
of the parent inhibitor 1 (Fig. [1.2.0].1) with a pyridyl substituent. The N-heteroatom would
accommodate the dative (L-type) binding necessary for photodissociation. Thus, two derivatives
of the parent compound were synthesized, 2 & 3 (Fig [1.2.0].1). It then became necessary to
investigate the effect of increasing the basicity of the ligand on CST-K inhibition.

Figure [1.2.0].1 The inhibitors being investigated.

To do this, I synthesized a previously established compound (1) and two new derivatives
(2 & 3). I performed enzyme inhibition assays, and caged the most potent derivative to a RuII
chaperone. This resulted in complex 4 (Fig [1.2.0].2). After characterization and photolysis
examination, I performed CST-K inhibition studies in the dark (pre-irradiation) and in the light
(post-irradiation). The results were compared to those of previous studies.

5

Figure [1.2.0].2 The RuII complex being investigated.
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CHAPTER 2. REVIEW OF THE LITERATURE
2.1 ENZYMES
2.1.1 PROTEASES
Proteases are lysosomal proteolytic enzymes that are essential to the regulation and
function of many bio-physiological processes including immune response, growth and cell
signaling.24 There are five main types of proteases, named according to their active site residues:
aspartic (exempli gratia, CST-D), serine (exempli gratia, trypsin), threonine (exempli gratia,
ornithine acetyltransferase), cysteine (exempli gratia, CST-K) and metallo-proteases (exempli
gratia, gluzincin). These proteins are tightly regulated and are responsible for lysing substrates for
cellular and structural maintenance. However, when unregulated and mislocalized, proteolysis
leads to the development of diseases including inflammation, emphysema and cancer.
There are four main clans of proteases, classed by structure, fold and function. These are
the papain- and calpain-like proteases (CA), caspases and related proteases (CD), picornaviral and
related proteases (PA) and carboxy- and related proteases as organized by Rawling and Barrett.2425

These enzymes typically have an active site nucleophile, such as a thiol or hydroxyl, and a basic

residue that can function as an acid during catalysis. Importantly, cysteine proteases are stable to
the acidic conditions found in abnormal cells and at the site of bone resorption.11 The enzymes are
usually recognized and denoted by their S2, S1 and S1' binding sites according to the Schechter and
Berger method, shown in Fig. [2.1.1].1.26
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Figure [2.1.1].1 The enzyme subsites and the substrate residues, as named by the Schechter & Berger method. This
description considers that the amino acid residues of the substrate (or inhibitor) bind to the corresponding active
site.

2.1.2 CA PAPAIN-LIKE (CA) CYSTEINE PROTEASES
Cysteine proteases are enzymes found in various animals, plant and micro-organisms,
typically sharing similar sequences and folds.27 This family includes papain and similar plant
proteases, cruzipain and similar parasite proteases, and lysosomal (mammalian) cathepsins. There
are currently 13 described lysosomal cathepsins; 11 of which are sequentially-known and are
expressed in a variety of cells within the lysosome, or extracellularly. These are CST-B, CST-C,
CST-F, CST-H, CST-K, CST-L, CST-O, CST-S, CST-V, CST-W and CST-X. The sequentiallyunknown two, have been identified as CST-N and CST-T.28
Of the sequentially known cathepsins, CST-B and CST-L have the highest lysosomal
concentation.27 CST- V and S are tissue-specific. CST-V is found in the testis/thymus27 and CSTS in lymphatic organs such as the lymph node and the spleen11. In contrast, CST- F, L and X are
widely spread.27 Of the CA proteases, CST-L shows the highest proteolytic activity of the
lysosomal proteases. Most of the enzymes are endopeptidases with the exception of CST-C which
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is an oligomeric aminopeptidase. In addition to their main roles, CST- B and X can behave as
carboxypeptidases and CST-H, as an aminopeptidase. Cysteine proteases also process important
proteins outside of the lysosome (exempli gratia, thyroglobulin, a thyroid hormone source), and
are important for other cellular processes like apoptosis (CST- B and C) and MHC‡‡ class IImediated antigen presentation (CST- S and L).27 Mislocalization of cysteine proteases can
contribute to pathologies such as Alzheimer’s disease, multiple sclerosis, muscular dystrophy,
cancers and bone-related diseases. CST- B, H and L play a major role in cancer progression by
directly degrading the extracellular matrix or by activating other important proteases.
In enzyme-inhibitor binding interactions, the S2 and the S1' enzyme binding sites contribute
most to the selectivity and diversity of these enzymes.27 Interaction of P2, P1 and P1' inhibitor
residues with the respective enzyme subsite involves the main- and side-chain atoms, whereas the
interaction with P3 involves only the side chain atoms. Structure characterization has revealed that
S4, S3' and further binding sites are not present on the cysteine proteases, although P 4 and P5
residues can interact with the enzyme. As such, the term “substrate binding site” usually refers to
the S2-S2' region.
2.1.3 CATHEPSIN K
CST-K is an important cysteine protease, mainly found in lysosomes.11 The recombinant
CST-K enzyme was characterized in 1996, after CST- B, H and L. The human enzyme is 329
amino acids long with a 215 amino-acid-long catalytic unit, a 99 amino-acid-long propeptide unit
and a 15 amino-acid-long N-terminal sequence, see Fig. [2.1.3].1 for the X-ray crystal structure.
Inhibitors for this enzyme are rarely selective because the amino acid sequence is 60% identical to
CST- L, S and V, and 35% identical to CST- B, F, H, O, and W.11, 27, 29 All cathepsins share a

‡‡
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common fold and have two domains: an N-terminal (left) and a C-terminal (right) with a V-shaped
active site cleft located between S1 and S1' as in Fig. [2.1.1].1. The enzymes interact with their
substrate at this special pocket called the active site that is decorated with amino acid residues and
subsites as seen in Fig. [2.1.1].1. 9, 25 The active site of CST- K is comprised of residues His159,
Cys25 and Asn175. The lysis performed by the enzyme occurs at the catalytic site (V-shaped cleft)
within the active site. The surrounding subsites are matt with amino acids as well. As an example,
the S2 subsite of the enzyme is defined by Tyr67, Met68, Ala133, Leu157, Ala160 and Leu205
according to papain residue numbering.
Cathepsin K is predominantly expressed in macrophages and osteoclasts.30 In
macrophages, it is 100-fold higher in concentration than CST- L and S. Once it diffuses across the
cell membrane it is ionized and sequestered by lysosomes but is transported between endosomes,
lysosomes and phagosomes.3 However, it can be secreted as an inactive glycosylated
preproenzyme precursors from osteoclasts, macrophages, fibroblasts and malignant cells and
sequestered into the resorption lacuna in the extracellular environment.
CST-K contributes enormously to skeletal development. It is well-known that a deficiency
in the enzyme may induce pycnodysostosis (abnormally dense bones) caused by a reduction in
bone reabsorption.30 The inhibition of CST-K causes undigested collagen fibrils to accumulate in
lysosomes. CST-K performs regulated functions in physiological processes of normal cells, but is
primarily concerned with collagenolytic and bone maintenance. This critical bone reabsorbing
protease is responsible for the regulatory functions in bone resorption, and it degrades type I/II
collagen, osteopontin and osteonectin (proteins that make up over 90% of bone). Following acidinduced demineralization of the bone, CST-K is secreted from the osteoblasts, causing proteolytic
degradation of the organic framework, id est, the type 1 collagen fibers. As the activity of CST-K
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is not regulated in abnormal cells, the imbalance and secretion is therefore associated with
pathological conditions and the onset of various diseases not limited to rheumatoid arthritis,
osteoporosis, atherosclerosis, inflammation, and cancer.3 It is the enhanced secretion of CST-K
and therefore the enhanced degradation of the collagen matrix that causes osteoporosis.25 CST-K
is upregulated by osteoclastogenesis factor, RANKL§§, and down-regulated by estrogen.

A

B

Figure [2.1.3].1 Crystal structure of Cathepsin K (A) by amino acid residue (JSmol-Javascript), (B) by
secondary structure (PV-WebGL). Image from the RCSB PDB (www.rcsb.org) of PDB ID 5TUN (S. Law, P.M.
Andrault, A. Aguda, N. Nguyen, N. Kruglyak, G. Brayer, D. Bromme (2017) Identification of mouse cathepsin
K structural elements that regulate the potency of odanacatib Biochem. J. 474: 851-864).

§§
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2.2 INHIBITORS
The ideal cysteine protease inhibitor has a low molecular weight, minimal peptide
character, high selectivity, high specificity, lipophilic character (to allow cell permeability) and
reversible target-binding ability (to avoid antigenic and immunologic complications).11
Additionally, inhibitors are most useful if they have good pharmacokinetic properties such as good
oral bioavailability, high membrane permeability, low toxicity, slow elimination rate and align
with Lipinski’s rule of 5. Most importantly, inhibitors should be unreactive under physiological
conditions, but selective and reactive enough to interact with the target. Selectivity of the cysteine
protease inhibitors is one of the most important and difficult properties to design due to the high
homology of the CA clan. Successful and selective inhibitors of CST-K are used to treat
osteoporosis, osteoarthritis, as well as, metastatic bone diseases associated with breast, lung,
thyroid and prostate cancers.
The peptide aldehydes, leupeptin and antipain (5 & 6; Fig [2.2.0].1), were the first synthetic
cysteine protease inhibitors designed.11 They are capable of inhibiting both serine and cysteine
proteases. E64 and peptidyl diazomethanes (7 & 8; Fig [2.2.0].1) were synthesized shortly after,
for the selective inhibition of CST- B, H and L. These were the only known cathepsins of the time.
To date, there are several types of inhibitors classed according to their mechanism of interaction
with the enzyme. Protease inhibitors can inhibit enzymes by alkylation, acylation,
phosphonylation, sulfonylation, metalloid binding, hemiacetal formation, pinner-type reaction, et
cetera. (See Table [2.2.0].1) Due to the extracellular localization of CST-K in cancers and
metatheses, non-lysosomotropic inhibitors may increase selectivity and limit the inhibition of
intracellular CSTs.
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Figure [2.2.0].1 Four of the first inhibitors synthesized.

Alkylation
Halomethyl Ketones
Diazomethyl Ketones
Acyloxymethyl Ketones
Epoxides
₪
₪
₪

Epoxysuccinyl
R,-Epoxyketone
R-Aminoalkyl Epoxide

Aziridine Derivatives

Acylation/ Imidation

Phosphonylation /
Sulfonylation/ Other

Aza-peptides
Carbamates
Peptidyl Acyl Hydroxamates

-Lactams
Heterocyclic Inhibitors
₪ Isocoumarins
₪ Benzoxazinones
₪ Saccharins

Peptide Phosphonates
Phosphonyl Fluorides
Sulfonyl Fluorides
Metalloid binding
Hemiacetal formation

Pinner-type
₪ Cyanamides
₪ Aromatic nitriles
Azodicarboxamides
₪ Aminoacetonitriles
Table [2.2.0].1 Major CA cysteine protease inhibitors, categorized by their mechanism of attack.
Vinyl Sulfones

Of these inhibitors, irreversible covalent binders including epoxysuccinyl derivatives,
ketones and vinyl sulfones are deemed impractical for many pharmacological applications but
have been found especially useful in combating drug-resistant cell lines and diseases.31
Correspondingly, compounds that contain reactive functional groups may cause an acute or
delayed toxic response by binding glutathione and/or DNA and must be well studied.30 The
inhibitors listed above are referred to as covalent modifiers because they inhibit the cysteine
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proteases by forming an irreversible or reversible covalent bond. Alternative inhibitors do not
possess an electrophilic warhead and are referred to as non-covalent modifiers.11, 32-34 The most
common of these are arylaminoethylamides (9, Fig. [2.2.0].2) that were once probed by Novartis
Pharma.

Figure [2.2.0].2 Pinner-type inhibitors, the first aminoacetonitrile inhibitors and an example of an azapeptide
inhibitor.

Of significant interest to this thesis are Pinner-type inhibitors. The potency and selectivity
of Pinner-type inhibitors are due to the nitrile warhead that covalently bind the substrate. 30 The
authentic Pinner reaction is an acid-catalyzed reaction between a nitrile and an alcohol that
proceeds to form an amidine or an ester. In contrast, the enzyme-inhibitor pinner-type reactions
are reversible; they form a thioimidate adduct and dissociate to reform the nitrile and substrate.
There are three major classes, each of which are structurally related: cyanamides, aryl-nitriles and
aminoacetonitriles.30, 35 In cyanamides (R2N-C≡N; exempli gratia 10, Fig [2.2.0].2), the nitrile is
connected to an N-heteroatom. The presence of the N-heteroatom increases the electrophilicity of
the group due to the inductive effect, improving its CST-K activity, however, it is only moderately
selective. In aromatic nitriles (R5Ph-C≡N; exempli gratia 11, Fig [2.2.0].2), the warhead is attached
to an aromatic group. The electrophilicity of the warhead increases with increasingly electron
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withdrawing substituents and heterocycles. In aminoacetonitriles (R2N-R2C-C≡N; exempli gratia
12 & 13, Fig [2.2.0].2), the nitrile warhead is terminal to an amino group. These are typically
potent and selective, although they have intermediate and lowest electrophilicity. Clinically
developed odanacatib (17, Fig [2.2.0].2) is an example of this inhibitor type. The first nitrile
compounds used for cysteine protease inhibition are acetamidoacetonitrile (12) and
benzamidoacetonitrile (13) (Fig [2.2.0].2).9 Currently, dipeptide aminonitriles (as presented in this
thesis) and azapeptides (14, Fig [2.2.0].2) are being competitively developed for CST-K inhibition.
In azapeptides, the CH group of a peptide is replaced by an N-heteroatom. When this is done at
P1, a more potent and stable inhibitor was observed in comparison to the carboanalogue.

36

Increasing electrophilicity and reactivity of the nitrile, can produce irreversible covalent binding
to cysteine proteases.35 Naturally occurring CST-K inhibitors include proteins of the cystatin,
stefin, kininogen, thyropin, serpin families and 2-macroglobulin.3
To date, three of the most promising CST-K inhibiting drugs were Balicatib (15), Relacatib
(16) and Odanacatib (17), see Fig. [2.2.1].3.11 Balicatib (AAE-581) is a highly potent, basic
peptidic nitrile having an IC50 of 1.4 nM with, however, low selectivity in cell based assays.2, 11 In
2006, the testing of the drug was discontinued by its developer, Novartis, during phase II clinical
trials when rare dermatological side effects, including lesions, pruritus, skin-thickening and other
phenotypes were observed.8,
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Relcatib (SB-462795) is a monobasic, extremely potent,

azepanaone analogue developed by GlaxoSmithKlein having a Kiapp of 41 pM and an oral
bioavailability of 89% among other suitable pharmacokinetic characteristic.2, 11 Clinical trials
toward the approval of this drug were however discontinued in 2007, possibly as a result of its low
selectivity, high lysosomic accumulation and off-target selectivity.8, 37 Until 2016, Odanacatib
(MK-0822) showed promise and quickly approached approval.8 It is a non-basic, non-

15
lysosomotropic, nitrile based inhibitor, with a high potency and selectivity for CST- K with an
IC50 of 0.2 nM. Its selectivity was owed to the 4-fluoroleucine side chain at P2.11 It also showed
great pharmacokinetic parameters such as long half-life, slow elimination and metabolism.
However, after 12 years of clinical development, Merck & Co. were forced to discontinue
development due to an increased risk of cardiovascular events to clinical patients.37

Figure [2.2.0].3 Three clinically developed CST-K inhibitors.

This thesis is based on the use of nitriles inhibitors, because they are both selective for the
CA cysteine protease clan, as well as, within the clan depending on the structure of the inhibitor.25
Once the inhibitor locks into the active site cleft where it is stabilized by a number of amino acid
residues, it is attacked by the thiol catalytic site, see [Fig. 2.2.0].4. Nitrile inhibitors have a higher
inhibitory activity toward cysteine proteases versus serine proteases. This observation is supported
by a number of theories. Firstly, the Hard-Soft Acid-Base (HSAB) theory, presumes that the soft
cyano (C≡N) electrophile binds much more tightly to the soft sulphur (S) nucleophile than the hard
oxygen (O) nucleophile. Secondly, the peptide nitriles reversibly bind the thiol of the cathepsin
via a covalent thioimidate linkage (18, Fig [2.2.0].5). 25, 30 When the nucleophilic thiol attacks the
sp carbon of the C≡N, a trigonal planar thioimidate is formed. As a result, the trigonal planar
intermediate is less prone to hydrolysis; it resembles the acyl enzyme rather than the hydrolysisprone tetrahedral intermediate of the sp2 carbonyls. Thirdly, the transition state of the nitrile
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interaction is less constrained in comparison to the serine-nitrile transition state due to the large
atomic radius of the S-heteroatom. As such, it is more likely for the adduct to revert than for
hydrolysis to take place. This is in contrast to serine proteases: the small size of the oxygen atom
may influence the reaction to proceed irreversibly to the competing hydrolysis of the substrate
molecule (see 19, Fig [2.2.0].5). In addition, the intermediate due to nitrile inhibition does not
require hydrogen bond stabilization since there is not an oxyanion hole formed as with carbonyl
inhibition.38

A

C
B

Figure [2.2.0].4 X-ray co-crystal structure of inhibitor 10 lodged into the active site cleft of CST-K and bound
by Cys139. (A) show the surface structure; (B) shows a magnified frontal view of the active site; (C) shows the
Cys139-S-C=N-R reversible bond via a magnified side view. Image from the RCSB PDB (www.rcsb.org) of
PDB ID 1YK8 (D. G. Barretta, D. N. Deaton, A. M. Hassell, R. B. McFadyen, A. B. Miller, L. R. Miller, J. A.
Payne, L. M. Shewchuk, D. H. Willard Jr., L. L. Wright (2005) Acyclic cyanamide-based inhibitors of cathepsin
K Bioorg. Med. Chem. Lett.15: 3039-3043).
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Figure [2.2.0].5 Proposed mechanism for cysteine inhibition versus serine inhibition.

Figure [2.2.0.].6 Depiction of the intermediate oxyanion hole that results from enzyme-carbonyl interactions.

Other structural implications of the dipeptide inhibitor play a large role as well. A study by
Löser et alia show that the P2 residue produces a different IC50 for cathepsins K, L and S in
accordance with the nature of the substituent: aliphatic/aromatic, bulky/compact, short/long, et
cetera.25 The authors noted the particular importance of the P2 residue in comparison to other
residues (P1 and P3). With reference to cathepsin K, the leucinyl substituent at P 2 had the highest
binding affinity for subsite S2. The phenylalanyl substituent also displayed favorable binding and
inhibitory activity. Table [2.2.0].1 shows that there is a specific length and bulk requirement for
high binding affinity to S2. The IC50 also increased with aromatic bulk on the N-terminal group
(P3); enhanced inhibitory activity was observed when carboxybenzyl (Cbz) substituent was used
at P3 rather that the tert-butyloxycarbonyl (Boc) substituent. The hydrogen bonding (HB) donation
from the N-H amide bond was shown to play a significant role in adduct stabilization; upon
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methylation of the amide N-heteroatom (N-Me), the affinity of the inhibitor for cells expressing
CST-K decreased by 3 orders of magnitude. Studies also show that the high cooperativity between
covalent and non-covalent interactions of the inhibitors and protease play a significant role, though
time independent inhibition was observed. Substrate specificity of CST-K is such that leucine is
favored over phenylalanine at P2. Cathepsin K inhibition with a basic P3 substituent was shown to
increase the enzyme selectivity as well as the lysosomal concentration. This increase in lysosomal
concentration can contribute to an increase in anti-target potency, and can reduce selectivity over
time.30

Table [2.2.0].2 Comparison of the inhibition constants of dipeptide inhibitors by the length and bulk of P 2 binding
site.
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2.3 PHOTO-CAGING: METAL-BASED ALTERNATIVES
2.3.1 ORGANIC CHROMOPHORES
The studies regarding organic-based chromophores and fluorophores far out-number the
investigation of the metal-based systems, and are continuously being develop as alternatives to
metals in renewable energy and medicine.39-41 Like metal-based chromophores, organic
chromophores are used to enable controlled, light-assisted protein inactivation or other cellular
functions. Of the most promising and grandfathered approaches are CALI and FALI, id est,
Chromophore/ Fluorophore-assisted light inactivation.42-46 This methods has primarily been used
to elucidate biological structure and function; it is useful in high-throughput applications because
of its characteristic efficiency.
For protein inhibition, an antibody labeled with malachite green dye is allowed to bind the
target protein followed by irradiation with laser light of suitable energy that excites the
chromophore.39 Coupling the dye to a protein-specific antibody leads to generation of singlet
oxygen (1O2). This causes irreversible damage to the bound protein, disturbing its normal function
and the function of proteins in its immediate vicinity. The inactivation is restricted to the protein
bound by the antibody. This method has been adapted for many different proteins including
membrane receptors, signal transduction molecules as well as transcription factors.
Commonly, the fluorophore fluorescein (28, Fig. [2.3.1].1) has been used for protein
labeling. It is water soluble, stable at and above pH 7 and is commercially available as an
isothiocyanate derivative.39 The absorbance of fluorescein, over the UV-vis range, increases
linearly with the dye concentration. Binding fluorescein to an antibody in an air-saturated solution
slightly increases the triplet lifetime. This is in contrast to the decrease in the triplet lifetime
observed when the solution is anaerobic. Collision with oxygen will potentially quench the
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chromophore since its photochemical (ground, singlet, triplet state) properties do not change upon
coupling. As such, binding an antibody to the chromophore (spatial shielding) protects the photoefficiency by preventing collision with oxygen. However, this method is prone to light-induced
protein inactivation, depending on the irradiation energy, enzyme, fluorophore concentration,
oxygen quenching, et cetera. Photo-bleaching is also an undesired side reaction that is independent
of protein inactivation.

Fig [2.3.1].1 Organic photo-activatable molecules described in this section.

Organic fluorophores have also been used as drug chaperones or photo-responsive drug
delivery systems (PDDSs), affording spatio-temporal control over biological activity or inhibition.
A wide range of organic groups are useful for application as PDDSs47-48, these include but are not
limited

to

o-nitrobenzyl15,

acridin-9-ylmethyl49,

acetylpyrene50,

hydroxyquinoline51,

hydroxylnapthyl52 and coumarinyl19, 53 derivatives.
Boron-dipyrromethene- (BODIPY-) derived photo-caging groups (29, Fig. [2.3.1].1), have
been proposed as an alternative to popular o-nitrobenzyl photo-caging systems resulting from their
superior optical properties, ease of synthesis and biocompatibility.54 Goswami et alia reported
successful photo-release of a carboxylic acid from the organic chaperone using visible light. The
authors also observed an increase in fluorescence (green light excitation) upon release; this likely
results from the carboxylic acid quenching the fluorescence while attached.

21
Of late, a hybridized strategy is the use of dual PDDSs that allow simultaneous photorelease of different therapeutics. Venkatesh et alia have probed the acetyl carbazole group for this
application with carboxylic acid and aminoacids.55 Carbazoles are deemed useful due to their wide
band gaps, luminescence efficiency and flexible functionalization making them potential
fluorescent PDDSs. Acetyl carbazole (30, Fig. [2.3.1].1) was reported as both a fluorescent
imaging agent as well as a potential PDDS. Caffeic acid (anti-tumor, anti-metastatic agent) and
chloroambucil (methylating agent in leukemia) are the photo-releasable drugs used (see 30, Fig
[2.3.1].1). Synergistic effects are also reported. With irradiation of the organic compound for 60
minutes with UV light (365 nm), 91 and 94% of the drugs were released with quantum yields of
0.046 and 0.051, respectively. Photo-decomposition of the free carbazole after 60 minutes of
irradiation is however, a drawback. The authors also reported biocompatibility and cellular uptake
activity using confocal microscopy studies on glial cancer cells U87MG, as well as high to low
cell viability before and after irradiation.
While organic-CALI provides the generation of a chimera of molecules that can selectively
bind and inhibit target proteins, polypyridyl-[RuII]-CALI is superior.23 Both the organic- and
[RuII]-based systems are highly efficient. These chemical reagents allow biological scientists to
carry out time-resolved studies on cellular dynamics. Organic chromophores are sensitive to selfbleaching and are often cell impermeable. They also lack high affinity and selectivity for the
proteins of interest. [RuII]-CALI chromophores have surpassed organic chromophores as they are
more resistant to photo- and self-bleaching (stable to singlet oxygen), are cell permeable and can
quantitatively inactivate selected proteins. They also have a longer triplet state lifetime, a higher
turnover of singlet oxygen, high affinity to synthetic binding proteins due to photo-physical and
photo-chemical properties.
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2.3.2 NANOPARTICLES
Lanthanide-doped up-converting nanoparticles (LD-UCNP) are of growing interest to the
field of spatio-temporal controlled therapy.16 The most prominent feature of these systems is the
anti-stokes property. This involves the vibrational excitation of a photon to a higher rather than
lower energy level (up-conversion) and results from the photo-physical property of the lanthanide
atom used. This is a property that renewable energy and data storage scientist have used for
decades and is now being probed for use in biological systems. LD-UCNP are known for their
high photostability, deep tissue penetration and activation with low energy near-infrared light
(NIR) which makes them even more attractive for use in bio-imaging with a diverse number of
functional groups.56
Li et alia have suggested the use of LD-UCNP in the study of biological processes,
regenerative medicine and cell isolation therapy.57 The researchers presented a strategy for noninvasive, spatio-temporal controlled therapy through the regulation of cell-material interactions:
photo-controlled cell adhesion. Prior to irradiation the cells were immobilized to TmYb-doped,
silica-coated, NaYF4 nanoparticles using a photo-cleavable molecule, a polyethyleneglycol spacer
and a bio-adhesive ligand. The up-converting property becomes necessary because ultraviolet
(UV) light is needed to activate the controlled photo-release of adhesion cells. As such, NIR of
980 nm irradiates the LD-UCNP that converts it to UV light. The UV light is absorbed by photolabile linkers that activate the photo-cleavage reaction and this changes the cell binding state of
the surface, causing adhesive cells to dissociate. In contrast, the use of intense UV light limits
tissue penetration and results in cellular and DNA damage. This strategy has the advantage of
causing little cell damage and extraordinary tissue penetration. The rate and the amount of cells
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released is also variable depending on the time of exposure to light and the power intensity of the
light used.
LD-UCNP are also being developed for use with the uncaging of photo-labile compounds
and bioluminescence imaging studies.56 Yang et alia report the use of the same UCNP listed above
for the enhancement of bio-imaging protocols. In this study, a D-luciferin-conjugated LD-UCNP
(31, Fig. [2.3.2].1) is activated by NIR irradiation, it then converts the energy to UV irradiation
which triggers the release of the D-luciferin which enhances the fluorescence and bioluminescence
signals in vitro and in vivo with light penetration of up to 10 mm of tissue. This procedure allows
non-invasive

monitoring

of

dynamic

biological

systems.

PEG – polyethylene glycol linker
Figure [2.3.2].1 The D-luciferin conjugated LD-UCNP described above.

2.3.3 OTHER ALTERNATIVES
Other methods to improve the bio-imaging and photolysis protocols include multiphoton
photolysis20, 58-60, uncaging of biological stimuli from nanocapsules61 and photo-induced electron
transfer62.
Multiphoton excitation
The most common type of multiphoton photolysis used is two-photon photolysis; a process
through which a photo-activated system simultaneously absorbs two photons of pulsed, lowenergy, visible, NIR or (far-infrared) FIR light using sufficiently intense laser illumination.63 The
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excitation produces results equivalent to that of single-photon excitation; however, the two are
quantum-mechanically different. Single-photon excitation is linear, whereas multiphoton
excitation is quadratic, id est, the fluorescence emission increases quadratically with excitation
intensity.64 Contrary to the popular notion, single and two photon excitation produce equivalent
results when the sum of the energies of the two photon excitation is greater than the energy gap
between the ground and excited state. (Fig [2.3.3].1)63

Fig [2.3.3].1 Jablonski diagram for single- and two-photon absorption.

The two-photon excitation process benefits from depth discrimination and enhanced 3D
resolution, for tissue penetration and imaging.64 With the new method, a wider range of
fluorophores are now available with limited cellular damage, but the probes must have long
wavelength absorption properties. Although two-photon excitation minimizes photo-bleaching
and photo-damage, cells and biological systems still experience these effects.63 Two-photon
damage may be caused by the production of reactive oxygen species (ROS), thermal damage from
high power infrared irradiation, as well as dielectric breakdown of proteins from the intense
electromagnetic field of the femtosecond laser. Two-photon excitation processes also have lower
conversion efficiencies due to the narrow absorption cross-section and require a more elaborate
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experiment set-up. The chemical probes used are required to have a high two-photon cross-sections
in reference to fluorescein.18 Brown et alia have reported the use of two photon excitation to photocleave chelates and calcium dyes thus giving researchers an opportunity to determine the role of
Ca2+ in cellular regulation and second messenger signaling using pulsed 700 nm light from a 7
mW powered laser.58
Chromophore-gated vesicles
Another attractive platform involves the use of lipid, polymer or silica vesicles to cage an
array of biologically active compounds, from small neutral and charged molecules to large
proteins, peptides and DNA (Fig [2.3.3].2).61 It avoids dark hydrolysis which usually causes
background activity, displays high photolytic efficiency and fast uncaging times. Their photolysis
wavelengths can be tuned by doping the nano-capsule shell with highly absorptive chromophores
such as 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO C18). The biomolecules are caged in the
vesicle by extrusion in phosphate-buffered saline containing 0.5–1 mM of the cageable
biomolecule, and occasionally with freeze-thaw cycles to increase capsulation efficiency. When
activating the vesicles in vivo, they can be visualized with a wavelength of light different to that
used for photolysis. Dendramis et alia were able to tune vesicles for uncaging in the FIR.61

Fig [2.3.3].2 Illustration of the photo-release of biomolecule such as carbachol form a chromophore-doped lipid
vesicle.
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Electron-controlled ligand release
Another method by which biological scientists can gain spatio-temporal control is via
biomolecule-release mediated by photo-induced electron transfer.62 It involves the design of
systems such that caging groups are removed by electron transfer rather than by direct photolysis,
id est, the bond-breaking step is independent of the light absorption step. This allows for even
greater control over the wavelength of light used in the release process. Mechanistically, a
sensitizer molecule and a quencher molecule are used. After the sensitizer is photolyzed, it
encounters the quencher while in its excited state. An electron is then transferred from the
sensitizer to the quencher creating a radical pair that partitions between (a) returning to the ground
state and

(b)

proceeding toward the desired products. The reactions are generally of four types:

sensitized reductive cleavage, direct reductive cleavage, sensitized oxidative cleavage and direct
oxidative mechanism. An example of this was reported using phenacyl esters via the sensitized
reductive cleavage by Banerjee and Falvey;62, 65 N-dimethylaniline as the sensitizer and phenacyl
ester as the quencher to produce a carboxylic acid, see Fig. [2.3.3].3.

Figure [2.3.3].3 An example of sensitized reductive cleaved of an organic carboxylic acid.
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2.4 PHOTO-CAGING: METAL-BASED
2.4.1 ABOUT METAL-BASED PACT & PDT
RuII complexes are being developed extensively for use in renewable energy production
and medicine. The use of RuII-complexes ([RuII]) in renewable energy includes the design of
photo-sensitizers and catalysts for high power output66 and for carbon dioxide reduction67. In
medicine, they are used as chemotherapeutics,68 and are being developed as photodynamic therapy
(PDT) agents 69 and photo-activated chemotherapeutics (PACT)70-72. The interest in metal-based
therapeutics increased shortly after 1978,73-74 when cisplatin became the first metal-based
anticancer therapy approved by the USFDA.75 Interest in [RuII] in particular, began with
investigations into transition metal.
Though it is not my focus, it is important to mention the alternative to photo-activatable
chemotherapy, PDT. PDT is continually being developed for use in cancer therapy, dermatology
and infections.76-77 Like PACT, it involves the excitation of a metal complex or an organic
molecule to the singlet excited state, after a photon of the appropriate energy is supplied. The
molecule can then return to ground state by radiative (fluorescent) or non-radiative (thermal)
decay. However, in an efficient photosensitizer the electron spin will rearrange to create a longlived triplet excited state. This is referred to as intersystem crossing. Upon decay from the triplet
excited state, the released energy can excite 1O2 to 3O2 (Fig [2.4.1].1). 3O2 will then be able to react
with other important molecules and proteins to trigger cell death. This is the main PDT mechanism
for biological damage, but the reliance on oxygen prevents its use in hypoxic microenvironments.
PDT agents are also prone to photo-bleaching, poor solubility and poor tissue retention. Other
methods of PDT include photo-initiated DNA binding.21 By this method, metal complexes bind
DNA after the photo-initiated release of a ligand. This strategy can be used in hypoxic
environments.

28

Figure [2.4.1].1 The essential electronic mechanism for the excitation of the 1O2 species to 3O2 in PDT.

Development concerning [RuII] in PACT requires a solid understanding of its electronic
dynamics. [RuII] are characterized by strong absorption throughout the UV-vis region, long excited
state lifetimes and chemical stability in solution. Added to these, [RuII] are highly reactive once
photo-excited but are generally inert at the ground state. When a photon is absorbed by a [Ru II],
an electron is excited from the ground state to a region of higher energy, 1MLCT. Intersystem
crossing then occurs as the electron is transferred to the 3MLCT. The MLCT can decay, id est,
return to ground state, via a radiative and non-radiative process or may populate thermally
accessible 3LF states (Fig [2.4.1].2). Ligand dissociation is completely dependent on the
population of this 3LF state.
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Figure [2.4.1].2 The electronic mechanism and energetic arrangements of the excited states that contribute to
depopoulation/population of the 3LF, influencing ligand dissociation.

The investigation presented in this thesis is a product of this tried, true and refined
property. Our work is in collaboration with the Turro group at Ohio State University. 5, 78-79 The
Turro group has tuned the 3LF state of the [RuII] such that bound cyano and pyridyl ligands would
easily dissociate from the [RuII] once irradiated. In the most recently tuned [Ru II], an ancillary
tridentate ligand, 2,2′:6′,2′′-terpyridine (terpy), has been used, accompanied by a bidentate ligand,
2,2'-bipyridine (bpy). The presence of the terpy ligand helps to distort the octahedral bond angles
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from the expected 90 and 180 degrees slightly, though most of the octahedral distortion is due to
the steric bulk of the bidentate ligand used, see Fig [2.4.1].3. Increasing the steric bulk on the bpy
ligand was found to increase the propensity of 3LF to be populated and therefore the lability of the
axial, monodentate ligand in low energy light. These researchers observed an increase of the
quantum yield for pyridine dissociation when 6,6′-dimethyl-2,2′-bipyridine (dmbpy) was used in
place of bpy on the [RuII]. These complexes were stable in the dark.
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32X

33X

Figure [2.4.1].3 Structural geometry of 32 & 33 via X-ray crystal structures, 32X & 33X. Image 32X from the
Cambridge Structural Database. CSD-JIMJUK C. R. Hecker, P. E. Fanwick, D. R. McMillin, Inorganic
Chemistry, 1991, 30, 659. DOI: 10.1021/ic00004a013. Image 33X from the Cambridge Structural Database.
CSD-ABAHUJ J. D. Knoll, B. A. Albani, C. B. Durr, C. Turro, Journal of Physical Chemistry A, 2014, 118,
10603. DOI: 10.1021/jp5057732.

Increasing the steric bulk of the bidentate ligand, distorts the pseudo octahedral
geometry of the complex even further and significantly tilts the active ligand. A 15 degree decrease
in the dihedral angle of the dmbpy is observed in comparison to the analogous bpy complex.
Consequently, the [RuII]-pyridine overlap decreases, the RuII-py bond is weakened and the
pyridine dissociation occurs more rapidly. Essentially, the energy of the 3LF state is lowered and
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is more easily populated; the  and  donation from pyridine is worsened and bond dissociation
is activated by photons. The energy of the lowest MLCT is not significantly changed because it is
unreactive toward substitution.
2.4.2 PREVIOUS WORK DONE BY THE KODANKO GROUP
An ideal chaperone is cleanly removable but has a high binding affinity to its substrate.62
It is stable prior to irradiation but removable with wavelengths of light that are not absorbed by
other components in its vicinity. It also has a high quantum yield for dissociation.
In organic chaperones it is difficult to satisfy all of the above features. Theoretically
speaking, once an inhibitor and a chaperone80 have been fine-tuned for inhibitory activity and
favorable dissociation, spatio-temporal control over protein inhibition can be gained by coupling
the two.79 Photo-activated compounds are constantly being developed due to their potential to act
as localized, specific, selective, time-gated therapeutics. This strategy has become essential in in
vitro and in vivo research applications and is being developed for clinical use.
[RuII(bpy)2]2+ is one of the most commonly used chaperones today. Prior to the
developments to be discussed in this thesis, senior authors of the Kodanko lab presented
[RuII(bpy)2]2+ as a chaperone for cysteine protease inhibitors.5, 79, 81 When [RuII(bpy)2]2+ is used,
two molecules of the monodentate inhibitors are bound to the metal center. The chaperone
therefore has dual-release capacity.5
In 2014, CST-K activity in osteoclast cells was targeted in an effort to spatially control
apoptosis, inflammation and cell signaling.79 The developed complex (34 & 35) were bound to the
RuII metal center via a dative bond to the nitrile (RuIIN≡CR) and had lower quantum yields than
the parent acetonitrile complex, 36, much like the CST-B complex described below. 34 & 35
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showed rapid and efficient dissociation of the first molecule, but inefficient dissociation of the
second identical ligand. The decreased efficiency for the release of the second inhibitor is a result
of

(a)

steric bulk around the complex preventing aquation,

(b)

the polarity and

(c)

larger size of the

monodentate inhibitor compound. In spite of this, the authors observed spatial and temporal control
over inhibition; the uncaged inhibitor and the irradiated complex inhibited the enzyme to the same
degree and the compound showed neither toxicity or growth inhibitory effects of BMM or PC-3
cells by MTT assays.

Figure [2.4.2].1 The first generation nitrile-bound inhibitors synthesized and investigated by the Kodanko group.

In a related study, a similar complex (37) was synthesized for the inhibition of CST-B.
CST-B is one of the most abundant proteases, overexpressed in human breast cancer. Upon
irradiation with 395 nm visible light, the protease inhibitors were released in vitro.
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Figure [2.4.2].2 The second generation nitrile bound [RuII-inhibitor] synthesized and investigated by the
Kodanko group.

The reported IC50 values were determined using the CST-B enzyme assay protocol.5 The
potency of the free inhibitor was similar to that of the caged inhibitor showing that inhibition was
prohibited once the inhibitor was caged to the chaperone fragment. The DLIR of the [Ru IIinhibitor] complex was found to be 12 via a CST-B enzyme assay. The inhibitory activity of the
complex increased once irradiated providing further evidence that the dissociation of the inhibitor
molecules is light controlled. Given that two inhibitor molecules were attached to the chaperone,
the IC50 value was expected to be at least half that of the free inhibitor. However, dual release was
restricted as a result of the low dissociation efficiency of the second caged inhibitor. The inhibitor
was also shown to be selective for cathepsin B using in vitro assays. In the triple negative breast
cancer cell line MDA-MB-231, the DLIR increased to 79.6; but did not change for Hs578T breast
cancer cell line. This is likely due to differences in protein complexation within each cell line. The
live cell proteolysis assay demonstrated that the irradiated complex was more potent than the free
inhibitor and could be used at lower concentrations. When 1 M of the compound (37) was photoactivated in a 3D MAME culture, the degradation of DQ-collagen IV (green fluorescence) was
significantly reduced. However, at higher concentrations significant inhibition was observed in the
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dark. This may be due to the release of inhibitor over the 4-day timescale of the experiment. The
complexes were not found to be toxic.
As we continued to develop photo-activatable inhibitors for CST-K82, we observed that the
stability of complexes in growth media was compromised when a RuII-N≡CR bond was present in
comparison to a RuII-pyridyl bond (Li, A.; Kodanko, J. Unpublished results). As such we
investigated pyridyl containing CST inhibitors and derivatives.
Our first publication displaying a pyridyl-bound [RuII-inhibitor] was targeted at CST-L and
papain inhibition via spatio-temporal controlled irreversible binding.83 Cathepsin L is a target
because of its influence in inflammation, cancer and other pathologies. Although the warhead was
not directly bound to the [RuII] as in the previously described complexes, the bulk of the metal
complex was expected to inhibit binding until photo-release. Previously established epoxysuccinyl
CLIK inhibitors were synthesized (38 & 41) and modified for caging (39 & 42). The second order
rate constant for inhibition (Ki) of CST-L by 38, 39, 40 (pre-irradiation) were experimentally
equivalent within error. Complexes 41 and 42 had similar inhibitory effects but 43 (pre-irradiation)
had a much lower inhibitory effect than 42. 43 (max = 471 nm) was only effective post-irradiation.
As such, 40 was presented as a homing agent whereas as 43 was presented as a spatio-temporally
controlled chaperone. The contribution of these investigations continue to pave the way for
targeting other enzymes and live cell systems and future in vivo work. The complexes continue to
be tuned and technology developed such that inhibition can be achieved spatio-temporally in the
PDT window***.

***

Range of light wavelengths (650–800 nm) suitable for photochemical excitation that avoids significant absorption of other plasma
components, including hemoglobin and water
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Figure [2.4.2].3 The parent inhibitors as well as their derivatives and caged inhibitors described above.

2.4.3 WORK BY OTHER RESEARCH TEAMS
Fighting cancer
Garner et alia reports a dual-action therapeutic agent, monitored by UV-vis spectroscopy,
1

H NMR and agarose mobility shift gels.84 Here, a derivative of uracil and an analogue of 5-

fluorocil, 5-cyanouracil (5-CNU), was complexed to [RuII(bpy)2]2+ via the nitrile substituent, see
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44, Fig [2.4.3].1. Once complexed, 5-cyanouracil was biologically inactive but activate upon
irradiation in water. The authors discern that the complex displays dual-therapeutic capabilities
since both the chaperone and the nucleobase (5-CNU) are functional after irradiation. As 5cyanouracil is released from the complex, simultaneous aquation of the metal complex enables
binding to DNA, initiating apoptosis in a mechanism similar to cisplatin. The authors propose that
5-cyanouracil disrupts the pyrimidine catabolism cycle pharmacologically. Importantly, the dualtherapeutic ability of the unit can also be controlled spatio-temporally and can therefore selectively
target malignancies, tumors and other effects with lower risks.
In 2013, the Turro group enhanced their photo-activatable system by using a new RuII
chaperone: [RuII(terpy)]2+.85 The chaperone was now bound to three 5-cyanouracil ligands; having
triple-release capacity, see 45, Fig. [2.4.3].1. Once irradiated with 395 nm light, the 5-CNU ligands
are photolyzed from the [RuII], which simultaneously undergoes aquation, then covalently binds
DNA. The individual biological activity of the 5-CNU and the [RuII] makes this complex an
attractive, potential dual-therapeutic agent. The authors observed that nitrile bound [RuII] display
a greater ligand-exchange quantum yield in comparison to other complexes. Importantly the drug
absorbs in the PDT window. This, and the increased cytotoxicity of the compound make
[RuII(terpy)]2+ a more favorable chaperone than [RuII(bpy)2]2+. The trans-effect also plays a large
role here such that the 5-CNU ligand trans to the pyridine of terpy is least likely to dissociate; the
axial ligands are more reactive. The complex is being further developed to increase the quantum
yield of aquation and cell penetration ability. Importantly, this new system can be irradiated
selectively and specifically, unlike other [RuII] that have undergone clinical trials, such as 46 –
KP1019, that have a lower selectivity.
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Figure [2.4.3].1 Nitrile-bound inhibitor-chaperone complexes synthesized and investigated by collaborators Turro
group (44 & 45) and a non-photo-activatable RuII complex being clinically developed (46).

Fighting Antimicrobial Resistance
Like photo-active oncotherapy, photo-active antimicrobial therapy types include:
photodynamic antimicrobial therapy (PDAMT) and photo-release antimicrobial therapy
(PRAMT).86 Much like PDT, PDAMT works via generation of ROS and causes non-specific
damage to the bacteria, whereas PRAMT, like, PACT, allows spatial and temporal control
achieving targeted therapy and reduced systemic toxicity to the host as well as reduced
antimicrobial resistance.
This technology is currently being advanced to combat antimicrobial resistance.86-89
Antibiotic resistance results from the bacterial mutations and reduces the impact of drugs on its
reproduction and life. Bacterial infection and resistance, lead to increased mortality and increase
health expenditure. Smith et alia tackles this growing problem by using [RuII(bpy)2]2+ as a
chaperone for an antimicrobial drug, isoniazid (INH).86 The photo-activated complex,
[RuII(bpy)2(INH)2]2+ (47) was shown to be 5.5 times more potent toward Mycobacterium
smegmatis than the unbound clinical drug, with a minimum inhibitory concentration of 4 M after
irradiation. Both INH ligands were released in less than two hours when irradiated with 465 nm
light, forming the diaqua complex: [RuII(bpy)2(H2O)2]2+. The first ligand dissociated within one
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minute of irradiation, or in less than 500 ps according to DFT calculations. It is likely that the
chaperone plays a role in either transporting the drug across the membrane or has an additional
antimicrobial mechanism in synergy with the released drug. The successful development of this
system as a therapy would mean the treatment of the third most important, multi-drug resistant,
mycobacterial disease worldwide, tuberculosis would be possible.

Figure [2.4.3].2 The PRAMT agent discussed above.
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Chapter 3. Methodology
3.1 MATERIALS
All declared materials were used as received without further purification from commercial
suppliers. Cbz-Phe-OH, Boc-4PA-OH, Boc-Phe-OH, HBTU and 4-nitrophenylcarbonate were
obtained from Chem-Impex International, Inc. Trifluoroacetic acid, 12 N hydrochloric acid,
sodium bicarbonate, sodium sulfate, sodium hydroxide, N-methylmorpholine, terpyridine,
acetone, ethanol, methanol and dry diethyl ether were obtained from Sigma-Aldrich Co. LLC.
Triethylamine, sodium chloride, dichloromethane, ethyl acetate and hexanes were obtained from
Fisher Chemical-Thermo Fisher Scientific, Inc. Celite and dry dimethylformamide were obtained
from Merck & Co., Inc. Formic acid, lithium chloride and toluene were obtained from EMD
Millipore Corporation. Diisopropylethylamine, benzyl chloroformate and sodium carbonate were
obtained from Acros Organics-Thermo Fisher Scientific, Inc. Aminoacetonitrile hydrochloride
was obtained from Alfa Aesar-Thermo Fisher Scientific, Inc. Pyridine-4-methanol was obtained
from Matrix Scientific. Ruthenium (III) chloride trihydrate was obtained from Strem Chemicals,
Inc. Dmbpy was obtained from Ark Pharma, Inc. Deuterated NMR solvents were obtained from
Cambridge Isotope Laboratories, Inc. Recombinant human procathepsin K (0.023 mg/mL; purity
> 95%) and Cbz-Phe-Arg-AMC (10 mg; purity > 99%) was commercially obtained from Enzo
Life Sciences, Inc. and the appropriate aliquots were prepared and frozen. Air sensitive reactions
were conducted in an atmosphere of nitrogen gas or argon gas obtained from Airgas, Inc. Column
chromatography was performed using silica gel obtained from Sigma-Aldrich Co. LLC and
alumina gel (activated, neutral, Brockmann Grade I) obtained from EMD Millipore Corporation.
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Synthesis of compounds 1, 2, 3 and 4 were accomplished using advanced intermediates.
All compounds were prepared using methods as stated in the literature, or using slightly modified
versions.
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3.2 INSTRUMENTATION
Thin layer chromatographs were collected using silica gel glass plates with UV-254
fluorescent indicator and alumina gel glass plates with UV-254 fluorescent indicator obtained from
Merck & Co., Inc. The 1H NMR spectra were collected on a Varian Fourier Transform (FT)
Nuclear Magnetic Resonance (NMR) Mercury 400, processed using Varian Vnmrj 2.2D software
or Varian FT-NMR Agilent 400, processed using Varian Vnmrj 3.2A software. The mass spectra
were obtained using Waters High Performance Liquid Chromatography (HPLC) ZQ2000 Single
Quadrupole Mass Spectrometer coupled with electrospray ionization. The UV-vis spectra were
obtained using a Varian Cary 50 spectrophotometer. Enzymatic assay plates were read using a
Tecan Infinite M200 microplate reader with Tecan i-control 1.10.4.0 software. Enzyme assays
were irradiated with an Osram Xenophot HLX 24 V/250 W Tungsten Halogen Lamp. A 10 cm
water cell was used to absorb unwanted infrared light. Inhibition data was fit using Igor Pro 7.00
32-bit software.
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3.3 PROCEDURES
3.3.1 SYNTHESES
Synthesis of Inhibitor 1

Figure [3.3.1].1 Reaction scheme for synthesis of Inhibitor 1.

Inhibitor 1 was prepared following a previously established method.81 A 10 mL round
bottom flask containing 48, Cbz-Phe-OH (250 mg; 0.84 mmol), was purged with N2 gas for 5
minutes; the flask was maintained under N2 gas for the remainder of the experiment. Dry DMF (6
mL) was then added to the flask and the mixture was stirred until dissolution of 48. HBTU (380
mg; 1.0 mmol), aminoacetonitrile hydrochloride (92.7 mg; 1.00 mmol) and triethylamine (0.28
mL; 2.0 mmol) were then added. The reaction mixture was stirred at room temperature (23 °C) for
16 h. Complete conversion of reactant to product was verified by TLC analysis. The organic layer
was extracted using DCM (8 mL) and washed with 0.1 M HCL (10 mL; 2 times), followed by
saturated sodium bicarbonate (10 mL; 2 times) then brine (10 mL) and dried using sodium sulfate.
The organic layer was then filtered, concentrated in vacuo and the product was recrystallized from
ethyl acetate/hexanes. Yield 204 mg; 72%. The product was characterized by 1H NMR and MS,
see chapter 4. The characterization data agreed with previously reported data.
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Synthesis of Reagent 50

Figure [3.3.1].2 Reaction scheme for synthesis of Reagent 42.

Reagent 50 was prepared following a previously established method.90 A 50 mL round
bottom flask containing pyridine-4-methanol (1.00 g; 0.00916 mmol) and 49, 4nitrophenylcarbonate (3.07 g; 0.0100 mmol), was purged with N2 gas for 5 minutes and maintained
under an N2 atmosphere. DCM (17 mL) was added, followed by N-methylmorpholine (1.00 mL;
0.00916 mmol). The mixture was stirred at room temperature (23 °C) for 76.5 h. The reaction
mixture changed from a cloudy off-white colloid to a dark red-orange solution. Upon completion,
as determined by TLC analysis, the solvent was evaporated in vacuo. The residue was then
dissolved in ethyl acetate (40 mL) and filtered through sterile cotton. The compound was extracted
using 1 M HCl (50 mL; 4 times). The aqueous layers were combined, the pH increased to 9 using
saturated sodium carbonate. The pH was monitored with universal indicator paper. The product
was then extracted with DCM (30 mL; 4 times) then washed with brine (50 mL), dried over
anhydrous sodium sulfate and concentrated in vacuo. The product was recrystallized from ethyl
acetate/hexanes. Yield: 1.92g; 77%. The product was characterized by 1H NMR and MS, see
chapter 4. The characterization data agrees with previously reported data.
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Synthesis of Inhibitor 2

Figure [3.3.1].3 Reaction scheme for synthesis of Inhibitor 2.

Compound 52 was prepared following a method modified from the literature.81 A 100 mL
round bottom flask containing 51, Boc-Phe-OH (3.00 g; 0.0113 mol) was purged with N2 gas for
5 minutes; the flask was maintained under N2 gas for the remainder of the experiment. Dry DMF
(60 mL) was added and the mixture was stirred until dissolution of 51. HBTU (5.15 g; 0.0136
mol), aminoacetonitrile hydrochloride (1.15 g; 0.0124 mol) and DIPEA (7.10 mL; 0.0396 mol)
were then added. The reaction mixture was stirred at room temperature (24 °C) for 19 h. Complete
conversion was verified by TLC analysis. The organic layer was extracted using ethyl acetate (75
mL) and washed with saturated sodium bicarbonate (100 mL; 2 times), then brine (100 mL) and
dried over anhydrous sodium sulfate. The organic layer was then filtered, concentrated under
reduced pressure and recrystallized from ethyl acetate to yield white crystals. Yield: 2.93 g; 85%.
The product was characterized by 1H NMR, see chapter 4. The characterization data agrees with
previously reported data.
Compound 53 was prepared following previously established methods.25, 91 Compound 52
(550 mg; 1.8 mmol) was added to a 20 mL round bottom flask. Formic acid (8 mL) was added and
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the mixture and allowed to stir at room temperature (25 °C) for 16.5 h. DCM (5 mL) was added to
the round bottom flask and the mixture was evaporated in vacuo. Water (10 mL) was added and
the solution was basified to pH 9 using saturated sodium bicarbonate. The pH was monitored with
universal indicator paper. Compound 53 was extracted using DCM (10 mL). The organic layer
was dried over anhydrous sodium sulfate and concentrated in vacuo. Yield: 224 mg; 61%. The
product was characterized by 1H NMR, see chapter 4. The characterization data agrees with
previously reported data.
Inhibitor 2 was prepared following a method modified from the literature.90 A 10 mL round
bottom flask containing 50 (148.5 mg; 0.5416 mmol) and 53 (135 mg; 0.492 mmol) was purged
with N2 gas for 5 minutes; the flask was maintained under N2 gas for the remainder of the
experiment. Dry DMF (5 mL) was added and the mixture stirred until dissolution of 50 and 53.
Triethylamine (0.08 mL; 0.5 mmol) was then added. The reaction mixture was stirred at room
temperature (24 °C) for 12 h. Complete conversion was verified by TLC analysis. The organic
layer was extracted using ethyl acetate (10 mL) and washed with sodium bicarbonate (10 mL; 2
times), then brine (10 mL) and dried over anhydrous sodium sulfate. The organic layer was then
filtered, concentrated in vacuo and recrystallized from ethyl acetate/hexanes to yield white
crystals. Yield: 120 mg; 72%. The product was characterized by 1H NMR and MS, see chapter 4.
The characterization data agrees with previously reported data.
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Synthesis of Inhibitor 3

Figure [3.3.1].4 Reaction scheme for synthesis of Inhibitor 3.

Compound 55 was prepared following a previously established method.81 A 25 mL
round bottom flask containing 54, Boc-4PA-OH (500. mL; 1.88 mmol), was purged with N2 gas
for 5 minutes; the flask was maintained under N2 gas for the remainder of the experiment. Dry
DMF (10 mL) was added and the mixture stirred until dissolution of 54. HBTU (854 mg; 2.25
mmol), aminoacetonitrile hydrochloride (191 mg; 2.07 mmol) and DIPEA (1.10 mL; 2.25 mmol)
were then added. The reaction mixture was stirred at room temperature (23 °C) for 18 h. Complete
conversion was verified by TLC analysis. The organic layer was extracted using ethyl acetate (15
mL) and washed with saturated sodium bicarbonate (20 mL; 2 times), brine (20 mL) and dried
over anhydrous sodium sulfate. The organic layer was then filtered, concentrated in vacuo and
recrystallized from ethyl acetate/hexanes to yield white crystals. Yield: 563 mg; 99%. The product
was characterized by 1H NMR, see chapter 4. The characterization data agrees with previously
reported data.
Inhibitor 3 was prepared following previously established methods.25, 91 Compound 55
(20.0 mg; 0.657 mmol) was added to a 5 mL round bottom flask. Excess formic acid (1 mL) was
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added and the mixture was allowed to stir at room temperature (23 °C) for 18.5 h. DCM (5 mL)
was added to the round bottom flask and the mixture was evaporated in vacuo.
The concentrated product was then basified to pH 9 with saturated sodium bicarbonate and
cooled to 5 °C. The pH was monitored with universal indicator paper. The flask was maintained
under ice cooling. Benzyl chloroformate was then added dropwise to the mixture. Upon
completion, as monitored by TLC analysis, the product was extracted with DCM (5 mL), dried
over anhydrous sodium sulfate, evaporated in vacuo and recrystallized from ethyl acetate/hexanes
to yield white crystals. Yield: 8 mg; 36%. The product was characterized by 1H NMR and MS, see
chapter 4. The characterization data agrees with previously reported data.
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Synthesis of Complex 4 [RuII(terpy)(bpy)(2)](PF6)2

Figure [3.3.1].5 Reaction scheme for synthesis of Complex 4.

Complex 57 was prepared following a method modified from the literature.92 A 150 mL
sealed flask containing 56, RuIIICl3·3H20 (500. mg; 1.91 mmol) and terpy (446 mg; 1.91 mmol)
was purged with argon gas for 10 minutes in the dark. Ethanol (134 mL) was then added and the
flask was sealed. The reaction was allowed to proceed under reflux (82 °C) for 4 h. The mixture
was then allowed to cool to room temperature and the deep purple crystals were collected after
centrifuging and washing with ethanol. The crystals were allowed to dry in vacuo for 16 h. Yield:
796 mg; 94%. The product was characterized by 1H NMR. The characterization data agrees with
previously reported data.
Complex 58 was prepared following a method modified from the literature.93 A 75 mL
sealed flask containing compound 57 (262 mg; 0.589 mmol), dmbpy (163 mg; 184.24 mmol),
lithium chloride (250 mg; 5.89 mmol) was purged with argon gas for 15 minutes. Ethanol (32 mL)
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and water (16 mL) were then added under continued purging. TEA was subsequently added. The
reaction was allowed to proceed under reflux (85 °C) for 21 h. The mixture was filtered through
celite while hot and the filtrate was evaporated in vacuo. The compound was purified over alumina
in the dark. (Solid phase: alumina; Mobile phase: 0–5% Methanol/DCM) and recrystallized from
1% methanol/DCM/hexanes. Yield: 148.8 mg; 43%. The product was characterized by 1H NMR,
see chapter 4. The characterization data agrees with previously reported data.
Complex 4 was prepared following a method modified from the literature.78 A 15 mL
sealed flask containing compound 58 (10. mg; 0.017 mmol) and 2 (17 mg; 0.050 mmol) were
purged with argon gas for 15 minutes. Ethanol (2.5 mL) and distilled water (2.5 mL) were then
added. The reaction was allowed to proceed under reflux (97 °C) for 16.5 h. The solvent was
evaporated in vacuo and the product was washed with toluene. Product was purified via column
chromatography (solid phase: alumina; mobile phase: 0–10% methanol/DCM), and solvent
layering (ethanol/diethyl ether, 3 times) and vapor diffusion (ethanol/diethyl ether; 2 times). Yield:
7 mg; 49%. The product was characterized by 1H NMR and MS, see chapter 4. The
characterization data agrees with previously reported data.
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3.3.2 CHARACTERIZATION: SAMPLE PREPARATION AND DATA COLLECTION
NMR
Approximately 20 mg or twenty drops of the compound was dissolved in 0.6–0.8 mL of
the deuterated NMR grade solvent in an appropriately sized vial. The solution was then filtered
through cotton into another via then transferred to a 7 inch, borosilicate glass NMR tube (with an
inner diameter of 0.5 mm and an outer diameter of 10 mm). 1H NMR solvents were either
methanol-D4 or chloroform-D1 and the resonances were referenced to the residual methanol and
chloroform signals on the Varian FT-NMR Mercury 400 or the Varian FT-NMR Agilent 400 for
all applicable samples. Mass spectroscopy was performed in methanol for all applicable samples.
See chapter 4 for details specific to each compound and section 3.2 for details specific to the
instrument.
Mass Spectrometry
Approximately 0.1 mg or one droplet of sample was dissolved in 1–5 mL of HPLC-grade
methanol. A gradient of concentrations were prepared. The methanol was first injected into the
NMR three times, followed by 1 to 3 injections of the dissolved sample of varying concentrations.
The solvent peak was subtracted from the sample peak. The spectrum was compared to the isotope
mass model. See chapter 4 for details specific to each compound and section 3.2 for details specific
to the instrument.
Electronic Absorption Spectroscopy
Approximately one drop or 0.5 mg of the sample was dissolved in 1 mL of ACS reagent
grade solvent in a vial. The solution was then transferred to a 1 X 1 cm quartz cuvette, sealed with
a plastic septum and placed in the Varian Cary 50 UV-Vis Spectrophotometer at ambient
temperature. Absorbance versus wavelength data was plot using Igor Pro 7.0.
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3.3.3 PHOTOLYSIS OF INHIBITOR
The sample was prepared as stated above and transferred to a 1 x 1 cm quartz cuvette. The
electronic absorption spectrum was taken after 0, 1, 3, 5, 10, 15 and 30 minutes of irradiation with
white light from Osram Xenophot HLX 24 V/250 W Tungsten Halogen Lamp. Photolysis data is
shown in section 4.2.
3.3.4 ENZYME ASSAYS
Free CST-K Inhibition assay for 1, 2 & 3
Cathepsin K activity was determined using a method previously reported in the literature.5,
79

All solutions and substrates were kept on ice prior to and between uses during experiment set-

up. The primary buffer contained 400 mM sodium acetate, 4 mM EDTA, 0.01% Triton-X at pH
5.5. The activator buffer contained 400 mM sodium acetate, 4 mM EDTA, 8 mM DTT, 0.01%
Triton-X at pH 5.5. The experiment was carried out in triplicate on Corning® 96 Well Flat Bottom
Black Polystyrene TC-Treated Microplates.
The enzyme was activated with activator buffer (100 L; 8 nM CST-K) and 30 minutes of
incubation at 25 °C. Substrate (5 mL; 20 L) was prepared from 100 mM aliquot of Cbz-Phe-ArgAMC. 100 L solutions of the free inhibitor of various concentrations were prepared via serial
dilution from a DMSO stock solution of the inhibitors. Concentrations ranged from 4 nM to 0.4
mM. After incubation of the enzyme, 96-well flat black plates were filled with 25 L of activated
enzyme, and 25 L of inhibitor solution. A blank cell was also prepared. The plate was covered
with foil and the reaction was allowed to take place for 15 minutes, with gently agitation every 3
minutes. 50 L substrate solution was added to each well and the plate was immediately placed in
the plate reader and processed. Final concentrations are: 2 nM CST-K, 10 M Cbz-Phe-Arg-AMC,
1 nM–0.1 mM inhibitor, <1% DMSO.
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CST-K activity was determined by kinetic measurements via fluorometric detection of the
AMC hydrolysis product at 37 °C, every 1 minute for 30 minutes. The enzyme activities are
expressed as ratios; 100% activity is the activity observed in the absence of inhibitor. The IC50
values are shown in section 4.3 and were determined by plotting percent activity versus log10 of
the inhibitor concentration. The data was fit using a sigmoidal curve (Igor Pro 7.0).
Caged CST-K dark-light Inhibition assay for 4
CST-K activity was determined using a method previously reported in the literature.5, 79 As
above, all solutions and substrates were stored on ice when not in use in the experiment. The
primary buffer contained 400 mM sodium acetate, 4 mM EDTA, 0.01% Triton-X at pH 5.5; this
buffer was used for all dilutions with the exception of that of the enzyme. The activator buffer
contained 400 mM sodium acetate, 4 mM EDTA, 8 mM DTT, 0.01% Triton-X at pH 5.5. The
experiment was carried out in triplicate on Corning® 96 Well Flat Bottom Black Polystyrene TCTreated Microplates. Light and dark experiments were done separately.
The enzyme was diluted 110 times with activator buffer (100 L; 8 nM CST-K) and
incubated for 15 minutes at 37 °C. Substrate (5 mL; 200 M) was prepared from 100 mM aliquot
of Cbz-Phe-Arg-AMC. 100 L solutions of the free inhibitor were prepared in vary concentrations
via serial dilution (concentrations varying from 4 nM to 0.4 mM). After incubation of enzyme, 96well flat black plates were filled with 25 L of activated enzyme, and 25 L of inhibitor solution.
A blank cell was also prepared.
For the “light” experiment, photolysis was allowed to take place by placing the plate under
the Osram Xenophot HLX 24 V/250 W tungsten halogen lamp for 15 minutes. Infrared light was
absorbed using a 10 cm water cell between the lamp and the sample. The plate was gently shaken
every 3 minutes.
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For the “dark” experiment, all room lights were switched, the plate was covered with foil
and the reaction was allowed to take place for 15 minutes. The plate was gently shaken every 3
minutes.
50 L of the substrate solution was added to each well and the plate was immediately
placed in the plate reader and processed. Final concentrations are: 2 nM CST-K, 100 M Z-PheArg-AMC, 1 nM–0.1 mM inhibitor.
CST-K activity was determined by kinetic measurements via fluorometric detection of the
AMC hydrolysis product at 37 °C, every 2 minutes for 14 minutes. The enzyme activities are
expressed as ratios; 100% activity is the activity observed in the absence of inhibitor. The IC 50
values are shown in section 4.3 and were determined by plotting percent activity versus log10 of
the inhibitor concentration. The data was fit using a sigmoidal curve (Igor Pro 7.0).
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Chapter 4. Findings
4.1 CHARACTERIZATION DATA

Figure [4.1.0].1 1H NMR of Inhibitor 1.
1

H NMR spectroscopy of 1 was performed in methanol-d4, and the resonances were referenced to

the residual methanol signal on the Varian FT-NMR Mercury 400:  7.26 (m, 10H),  5.01 (q, 2H,
12.56, 14.19),  4.34 (dt, 1H, 2.43, 6.08),  4.10 (d, 2H, 2.84),  3.12 (dd, 1H, 6.08, 13.78),  2.88
(dd, 1H, 13.78)
MS (ESI) performed in methanol. m/z: [M + H]+ Calcd for C19H19N3O3: 337.14; Found :
337.96
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Figure [4.1.0].2 1H NMR of compound 50.
1

H NMR spectroscopy of 50 was performed in methanol-d4, and the resonances were referenced

to the residual methanol signal on the Varian FT-NMR Mercury 400:  8.57 (m, 2H),  832 (m,
2H),  7.52 (m, 4H),  5.39 (s, 2H)
MS (ESI) performed in methanol. m/z: [M + H]+ Calcd for C13H10N2O5: 274.06; Found:
274.87
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Figure [4.1.0].3 1H NMR of compound 52.
1

H NMR spectroscopy of 52 was performed in chloroform-d1, and the resonances were referenced

to the residual chloroform signal on the Varian FT-NMR Mercury 400: 7.33 (m, 3H),  7.20 (d,
2H, 7.30),  4.34 (m, 1H),  4.10 (m, 2H), 3.09 (d, 2H, 6.89),  1.41 (s, 9H)
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Figure [4.1.0].4 1H NMR of compound 53.
1

H NMR spectroscopy of 53 was performed in chloroform-d1, and the resonances were referenced

to the residual chloroform signal on the Varian FT-NMR Mercury 400:  7.33 (m, 3H),  7.20 (d,
2H, 7.30),  4.19 (d, 2H, 5.67),  3.68 (dd, 1H, 4.05, 8.92),  3.26 (dd, 1H, 4.05, 13.78),  2.76
(dd, 1H, 8.05, 13.78)
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Figure [4.1.0].5 1H NMR of Inhibitor 2.
1

H NMR spectroscopy of 2 was performed in methanol-d4, and the resonances were referenced to

the residual methanol signal on the Varian FT-NMR Mercury 400:  8.45 (d, 2H, 4.05),  7.26 (m,
7H),  5.10 (dd, 2H, 14.59, 20.27),  4.37 (dt, 1H, 5.67, 9.68),  4.12 (d, 2H, 0.81),  3.16 (dd, 1H,
5.67, 14.59),  2.88 (dd, 1H, 9.68, 14.59)
MS (ESI) performed in methanol. m/z: [M + H]+ Calcd for C18H18N4O3: 338.14; Found:
338.87
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Figure [4.1.0].6 1H NMR of Compound 55.
1

H NMR spectroscopy of 55 was performed in methanol-d4, and the resonances were referenced

to the residual methanol signal on the Varian FT-NMR Mercury 400:  8.45 (d, 2H, 4.46),  7.33
(d, 2H, 4.46),  4.38 (dt, 1H, 3.24, 5.67),  3.20 (dd, 1H, 5.67, 13.78),  2.89 (dd, 1H, 13.78), 
1.35 (s, 9H).
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Figure [4.1.0].7 1H NMR of Inhibitor 3.
1

H NMR spectroscopy of 3 was performed in methanol-d4, and the resonances were referenced

to the residual methanol signal on the Varian FT-NMR Mercury 400:  8.39 (d, 2H, 5.67),  7.30
(m, 3H),  7.25 (m, 2H),  5.07 (d, 1H, 12.56),  4.97 (d, 1H, 12.56),  4.44 (m, 1H),  4.14 (m,
2H),  3.22 (dd, 1H, 5.67, 14.44),  2.93 (dd, 1H, 9.32, 14.44).
MS (ESI) performed in methanol. m/z: [M + H]+ Calcd for C19H19N3O3: 337.14; Found:
337.88
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Figure [4.1.0].8 1H NMR of Compound 58.
1

H NMR spectroscopy of 58 was performed in methanol-d4, and the resonances were referenced

to the residual methanol signal on the Varian FT-NMR Agilent 400:  7.51 (d, 1H, 7.77),  7.37
(ddd, 2H, 8.31),  7.22 (d, 1H, 8.31),  7.14 (td, 1H, 1.47, 7.77),  7.01 (td, 1H, 1.47, 8.31), 
6.96 (d, 2H, 5.87),  6.90 (tt, 2H, 1.47, 7.83),  6.69 (d, 1H, 7.83),  6.57 (m, 1H),  6.36 (m,
2H),  5.82 (d, 1H, 7.83),  2.32 (s, 3H),  0.50 (s, 3H)
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Figure [4.1.0].9 1H NMR of Complex 4.
1

H NMR spectroscopy of 4 was performed in methanol-d4, and the resonances were referenced to

the residual methanol signal on the Varian FT-NMR Mercury 400:  8.74 (d, 1H, 7.83),  8.69 (m,
2H),  8.63 (t, 2H, 7.83),  8.47 (d, 1H, 7.83),  8.31 (t, 1H, 8.31),  8.26 (d, 1H, 5.87),  8.23 (d,
2H, 7.83),  8.17 (m, 2H),  7.80 (d, 1H, 7.83),  7.75 (m, 1H),  7.64 (m, 2H),  7.57 (m, 2H), 
7.18 (m, 4H),  7.10 (sext, 1H, 4.40),  7.01 (d, 1H, 7.83),  6.92 (t, 2H, 6.85),  4.93 (d, 1H, 6.85),
 4.26 (dd, 1H, 5.87, 9.29),  4.05 (d, 1H, 6.85),  3.08 (dd, 1H, 5.87, 13.83),  2.81 (dd, 1H, 9.29,
13.83),  2.03 (s, 3H),  1.51 (s, 3H)
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MS (ESI) performed in methanol. m/z: [M + H]+ Calcd for [C45H41N9O3Ru]+: 996.21, 997.21,
998.21, 999.20, 1000.20, 1001.20, 1002.20, 1003.20, 1004.20, 1005.21, 1006.21; Found: 996.33,
997.33, 998.29, 999.24, 1000.45, 1001.59, 1002.75, 1004.00, 1004.83, 1005.86, 1006.86
MS (ESI) performed in methanol. m/z: [M + H]2+ Calcd for [C45H41N9O3Ru]2+: 428.62;
Found: 428.55.

Figure [4.1.0].10 Superimposed UV-Vis Spectra of Complex 4 & 59. The UV-Vis spectroscopies of complexes 4
and 58 were performed using methanol. This confirms that a hexa-pyridyl complex was synthesized due to the form
of the spectrum and maximum absorption.

The experimental max values are as follows:
max of Complex 4 = 475 nm (w. shoulder at 421 nm)
max of Complex 58 = 500 nm.
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4.2 PHOTOLYSIS DATA

Figure [4.2.0].1 UV-Vis-Photolysis data.

The experimentation of complex 4 was performed in methanol. The hexa-pyridyl complex was not
observed after 1 minute of irradiation. This suggests that the monodentate pyridyl ligand was
release upon irradiation.
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4.3 DATA OF ENZYME INHIBITION ASSAYS

Figure [4.3.0].1 Enzyme assay data of the uncaged CST-K inhibitors.

The IC50 values of the free inhibitors were found experimentally using a CST-K enzyme
assay protocol. The error bars represent the standard deviation of the mean of three
independently prepared sample.
The experimental IC50 values are as follows:
IC50 of 1 = 67 nM
IC50 of 2 = 843 nM
IC50 of 3 = 942 nM
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Figure [4.3.0].2 Light inhibition enzyme assay data of the caged CST-K inhibitors plot against the respective uncaged
inhibitor 2.

Dark/light IC50 ratio of complex 4 was found using a CST-K enzyme protocol. The dark/light IC50
data of the caged inhibitor is plot against the free inhibitor, 2, for comparison. The error bars
represent the standard deviation of the mean of three independently prepared sample.

The experimental IC50 values are as follows:

IC50 of 4 (pre-irradiation) = 1035 nM

IC50 of 4 (post-irradiation) = 794 nM

IC50 of 2 (uncaged)

= 843 nM.
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Chapter 5. Clarifications & Contributions
This study was one in a series, being conducted by the Kodanko Lab that investigates (a)the
IC50 of modified, known inhibitors of cysteine cathepsins (CSTs) and (b)the light/dark IC50 ratio of
the RuII complexed inhibitor.83 In these studies, the known inhibitors were modified by replacing
a phenyl substituent with a pyridyl substituent. This allowed dative binding of the inhibitor to the
RuII chaperone at the nitrogen heteroatom.78 Prior to this investment, known dipeptide CST
inhibitors were caged at the nitrile group without modification.79 However, recent studies showed
that RuII chaperone had a higher binding affinity for the pyridyl group than the nitrile group. 78
Laboratory experiments also showed that the pyridyl-bound substances had a greater stability in
growth media (Li, A; Kodanko, J. Unpublished results). Other inhibitors that are modified and
investigated in this series, include irreversible epoxysuccinyl inhibitors,83 and reversible dipeptide
inhibitors reported here. The epoxysuccinyl inhibitors are being investigated for inhibition of CSTL and for papain binding affinity.83 They will be referenced in comparison to the dipeptide inhibitor
below. The reported dipeptide aminoacetonitrile inhibitor was investigated in relation to cysteine
CST-K.
CST-K is a regulatory endopeptidase.3 It binds the substrate at the active site and catalyzes
the lysis of the substrate at internal peptide bonds. The activity of these types of enzymes, is
therefore described according to its ability to bind a substrate and lyse its peptide bonds. At the
active site, the bond breaker (catalytic site) lies between subsites that lock specific substrates into
the active site. This active site generally has four important, well-elucidated subsites ranging from
S2 to S2', S3 is also well known, though less important. As such, inhibitors are synthesized such
that the P3 to P2' substituents have high binding affinity to their corresponding subsites. Other
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subsites beyond S3 and S2' have not been clearly elucidated, and are not usually a major focus in
synthesis. The dipeptide inhibitors presented here bind S3–S1.27

Figure [5.0.0].1 Schechter and Berger residue assignments for inhibitor 1.

As with previous research in the Kodanko lab,83 exchanging the phenyl ring at P2 or P3
with a pyridyl ring was expected to produce increased or similar inhibitory activity to the original
inhibitor. Binding of P3 to the [RuII] chaperone was also postulated to afford spatio-temporal
control over inhibition by way of steric hindrance and decreased binding affinity at P3.
The parent inhibitor used had previously been studied by Löser et alia.25 In 2005, they
showed that synthetic CST-K inhibitors are most active with hydrophobic leucinyl at the P2
position. However, the compounds presented herein avoid the use of leucinyl as there are no known
cageable of this group that would allow for a comparative analysis. The phenyl moiety was instead
exchanged with structurally similar pyridyl at P3 and P2 instead. The aromatic substituents interact
favorably with the S2 site of CST-K. The inhibitory activity of the cageable and uncageable
inhibitors were thus easily compared. The P2 side chain of the compounds under analysis is
therefore, either phenylalanyl or 4-pyridylalanyl, and the P3 side chain is either carboxybenzyl
(Cbz) or carboxy-4-pyridylmethyl (C4pz).
By IC50 analysis, inhibitor 2 was 13 times less potent than the parent inhibitor 1, and
inhibitor 3 was 14 times less potent than inhibitor 1. These results highlight the structural
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importance of the P2 and the P3 group and their interaction with the subsites of the enzyme. It is
also important to note that the structural change at P2 affected inhibition much more than the
structural change at P3. The findings are not in agreement with the hypothesis and prior studies.9,
83

The P1 residue-S1 subsite interaction
Because the S1 subsite is adjacent to the catalytic site, a well-tolerated binding or nonbinding residue is important for a high substrate binding affinity.3 Though a side chain seems to
be unnecessary at this site, a non-proteinogenic side chain was shown to increase the metabolic
stability, potency and binding affinity of the inhibitor.9 In an account by Altman et alia, inhibition
increased 4-fold when a benzyloxy group was placed at P1, in comparison to a hydride however,
increasing or decreasing the steric bulk from this point resulted in a loss of activity; S 1 seems to
be an all-or-nothing subsite. The P1 residue did not include a side chain for either of the amino
acids used.
The P2 residue-S2 subsite interaction
The S2 and S1' sites are responsible for the diversity and selectivity of the active site.3 S2 is
well known for accommodating elastic and bulky amino acids; it is a “true deep pocket” and plays
a significant role in in facilitating strong binding. This interaction in combination with the covalent
thioimidate formation is the most crucial to binding and inhibition.25 The importance of a side
chain at the P2 residue is unquestionable; when glycine is used the inhibitor is completely
unreactive. Rigidization and reduction of bulk at this reside typically reduces the potency of CSTK inhibition. One example of this is the change from leucinyl to phenylalanyl. The phenyl to
pyridyl exchange here makes for a slightly smaller aromatic ring and a more basic residue.
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Although introducing a basic heteroatom improves the solubility and reduces the metabolism of
inhibitors, it also increases the hydrogen-bonding capacity of the inhibitor and the hydrophilicity
of the residue.94 This destabilizes its interaction with the hydrophobic S2 subsite and stabilizes
interaction with residues in the vicinity of the active site, interrupting the usual binding
arrangement of the substrate.25 It is also important to note that the experiment were carried out at
pH 5.5. At this pH, the pyridine substituent is likely charged and less hydrophobic. These findings
support the established notion that the enzyme is selective at S2 and sensitive to changes at P2.
The P3 residue-S3 subsite interaction
S3 is less important and more promiscuous than S2 and S1 for substrate selectivity.27 The
locking of P3 into S3 is mediated only by side chain contact over its relatively wide area. In contrast,
both main and side chain contact is necessary for S2–S2' subsites. The S3 binding site has not been
well-defined, thus an accurate trend is yet to be cited. Bulkier substituents at P3 have been shown
to enhance the P3-S3 interactions, although, an increase in activity was observed when the tertbutyl moiety was replaced with the phenyl moiety.25 In these inhibitor analogues, the introduction
of the heteroatom typically affects binding much less than at the S 2 site;3 possibly due to an
increase in hydrophilicity.9 Polar residues were also found to be well-tolerated at S3. This is seen
in the IC50 increase from 7 to 8 shown in table [5.0.0].1. The decrease in activity that was observed
when the 4-pyridyl moiety was used is inconsistent with these findings.
These findings are in drastic contrast to the data reported by Huisman et alia.83 The authors
noted very little change in inhibition data when the inhibitors were modified. It is however,
extremely important to note that the target of Huisman’s inhibitors were papain and CST-L which
have different subsite characteristics, promiscuity and interaction requirements than CST-K. A
closer look at the inhibitors listed in this study also reveal that the inhibitor is able to lock into the
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enzyme at P3–P1 and P1' sites. Incorporating subsites on both sides of the warhead may increase
the binding stability of the inhibitor to the enzyme.

Table [5.0.0].1 Evidence for increase in efficacy due to increase in basicity at P3 residue, contrary to the
observation presented here

RuII-complexed inhibitor 4
Of the two modified inhibitors synthesized, the compound with the lowest IC50 was caged
to a RuII metal chaperone at the N-heteroatom of the pyridine. Previously, we caged the inhibitor
to the chaperone at the N-heteroatom of the terminal nitrile.79 The strategy for investigating
aminoacetonitriles changed quite a bit from previous studies due to increased stability in growth
media as described in the following paragraph.
In prior studies, the inhibitor was caged at the nitrile terminal rather than through a cageable
derivative of the inhibitor. This change was deemed necessary due to the instability of [RuII]-N≡CR
in growth media. The complexes could be unstable due to oxidation of RuII to RuIII followed by
the hydrolysis of the nitrile to an amide.95 However, the low dissociation quantum yield of
[RuII(bpy)2(py)2]2+ highlighted the need for a new chaperone.78 The [RuII]-py bond was too stable
for photodissociation. Knoll et alia reported a [RuII(dmbpy)(terpy)]2+ chaperone that surpassed the
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[RuII(bpy)2]2+ chaperone in pyridine photodissociation with a 27 fold difference in quantum yield.
As such, [RuII(dmbpy)(terpy)(py-R)]2+ derivatives are currently being studied and were used here.
The trend for increasing photodissociation quantum yield with increased steric crowding around
the metal center is also seen in other [RuII]. See table [5.0.0].29.

[RuII(terpy)(bpy)(py)]2+

Dichloromethane Acetonitrile
ɸ500nm= 0.16
ɸ 500nm <0.0001

[RuII(dmbpy)2(py)2]2+
[RuII(bpy)2(py)2]2+

ɸ436nm = 0.025
ɸ436nm = 0.0059

[RuII(terpy)(dmbpy)(py)]2+

[RuII(tpa)(py)2]2+ ɸ400nm = 0.0097
[RuII(tpa)(MeCN)2]2+ ɸ400nm = 0.016
[RuII(mtpa)(MeCN)2]2+ ɸ400nm =0.041
Table [5.0.0].2 Comparison of the quantum yields of dissociation for 3 sets of chaperones. The chaperones of
each set have different degrees of metal centered bulk.

The UV-vis photodissociation experiment showed the once irradiated, the inhibitor(s) was
photo-released within minutes using white light. As of late, RuII metal chaperones are tuned by
altering the heteroatomic bidentate ligand, bipyridyl. 78-79, 84, 96-97 Many analogues of bipyridyl have
been investigated for their effect on the rate of photo-release of active ligands. Heteroatomic
tridentate and tetradentate ligands have also been used. In the Kodanko lab, photo-caging work
started

with

[RuII(bpy2)]2+,

followed

by

[RuII(tpa)]2+

complexes,

and

now

using

[RuII(terpy)(bpy)]2+ complexes and derivatives. With this development came the acknowledgment
of pyridine as a cageable ligand.

9

tpa - tris(2-pyridylmethyl)amine
mtpa - tris(6-methyl-2-pyridylmethyl)amine;
MeCN - acetonitrile
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The metal chaperone used in this study was first investigated, by the Turro group at Ohio
State University, for efficient photodissociation of pyridine and pyridine derivatives.78, 97 Although
chaperones [RuII(bpy)2]2+ and [RuII(bpy)(terpy)]2+show good photodissociation for nitriles,
photodissociation is poor for pyridine and pyridine derivatives. This is due to the stability of the
complex and the strong [RuII]-py bond. Knoll et alia observed that an increase of steric bulk on
the ancillary ligands of RuII chaperones weakened the RuII-py bond, thus increased its quantum
yield of photodissociation. Steric bulk of the bidentate ligand was increased by placing methyl
substituents at the 6 and 6' positions of the bpy ligand: [RuII(dmbpy)(terpy)]2+.
The dark/light IC50 ratio (DLIR) in this experiment was expected to be significant based
on previously reported experiments.79 The DLIR is a measure of the ability of the chaperone to
prohibit inhibition prior to irradiation and facilitate inhibition post-irradiation. This is the main
facet being exploited for spatio-temporal control with PACT.
Respondek et alia reported a DLIR of 35 and 88 for complexes 35 and 36, respectively.
The DLIR of complex 4 is 1.3. The most obvious difference between 35/36 and 4 is the dualrelease capacity of 35 and 36 versus the single release capacity of 4, although this plays an
insignificant role in the observed ratio. Instead, the low DLIR is likely due to the ability of the
caged complex to inhibit the CST-K enzyme without irradiation. Recall the structural geometry of
4, Fig [1.2.0].2, the nitrile warhead is terminal to the complex and unhindered sterically or
otherwise. This is in contrast to 35/36, where the inhibitor is bound to the metal center by the
warhead, id est, both sterically and datively hindered. In such a case, it is extremely difficult for
the enzyme to interact with the warhead. The complex must first be photo-activated, enabling the
release of the molecule, before inhibition occurs. Whereas, in 4, no photo-activation is necessary
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since the nitrile warhead is dangling and unhindered. The low DLIR observed is a result of a similar
IC50 before and after photo-activated release.
This phenomenon was also seen in other experiments performed by a co-researcher in the
investigation of papain binding.83 Huisman et alia has reported a relative (dark v. light) second
order rate constant10 (krel) of 10 for complex 43, whereas complex 40 had a krel of 1. In complex
43, the inhibitor is caged such that the epoxysuccinyl warhead is sterically crowded and not easily
accessed by substrate prior to irradiation. Whereas, the epoxysuccinyl warhead of 40 is not
hindered and is open to attack showing little inhibitory difference whether caged or released, like
4. Smilarly, the metal complex may not have been bulky enough to prohibit binding to the CST-K
inhibitor. It is therefore fair to conclude that metallo-binding that renders the warhead unhindered
will not contribute to spatio-temporal control over CST inhibition in enzyme assays. These binding
arrangements should be coordinated such that the bulk of the ancillary ligands can obstruct
interaction with the CST enzyme.
This may also speak to the promiscuity and large size of the P3 site. It is also possible that
the P3 subsite is large and promiscuous enough to interact with the chaperone. It will be interesting
to discover whether the DLIR would be similar in vitro where there is a possibility Ru II-protein
complexation that may prevent binding of the caged inhibitor. Further investigations should also
include caging at P2 to determine whether there is enough steric hindrance to reduce inhibition
prior to irradiation of the caged inhibitor.

10

krel = (kinact/Ki)dark ÷ (kinact/Ki)light
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Chapter 6. Conclusion
In conclusion, a new binding protocol for RuII-dipeptide inhibitor complexes was
investigated. By the new protocol, inhibitors are bound by a pyridyl substituent,82-83 as an
alternative to the nitrile substituent previously reported by the Kodanko group.5, 79, 96, 98
The thesis describes the successful synthesis of a known CST-K inhibitor and two new
derivatives. Upon determining and comparing the IC50 of the inhibitors, it became evident that
increasing the basicity of the P2 and P3 residues decreases the efficacy of the inhibitor to bind to
the CST-K active site. These findings are not in complete agreement with previous studies.25, 83
The decrease in efficacy resulting from the increase in basicity at P2 is supported by the literature.
However, the decrease in efficacy resulting from the increase in basicity at P3 is not. The observed
deviation may be a result of side-interactions with ionic amino acid residues and hydrogen bond
donors and acceptors. The ability of the complex to bind CST-K before photo-release of the
dipeptide inhibitor also speaks to the size and promiscuity of the CST-K active site.
The inhibitors described have been successfully caged and photo-released form the
synthesized RuII chaperone. However, the resulting position of the nitrile warhead made it difficult
to achieve spatio-temporal control over CST-K binding. This results from the terminal and
unhindered position of the nitrile warhead.
The study has shown that for a substantial DLIR/krel to be established, the photo-activatable
complex must be designed such that the warhead of the inhibitor is hindered prior to photo-release
from the chaperone. This thesis will contribute to the conceptual development of Ru II-inhibitor
complexes and future studies of the Kodanko lab as spatio-temporally controlled protein inhibition
is pursued. From this and prior studies,5, 79, 83 it is so-far determined that successful spatio-temporal
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control is best achieved when the nitrile warhead is directly bound to the Ru II complex or
sufficiently shielded from attack by the substrate via other measures. As seen here, when the
warhead is terminal and far-removed from the RuII chaperone it is not sufficiently hindered so as
to avoid binding the substrate prior to irradiation.
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Abstract
DESIGN, SYNTHESIS AND ANALYSIS OF POTENTIAL PHOTO-ACTIVATABLE
CATHEPSIN K INHIBITORS
by
KHALIN EVANIA NISBETT
May 2017
Advisor: Dr. Jeremy Kodanko
Major: Chemistry
Degree: Master of Science
Tightly regulated cysteine CA proteases play a major role in maintaining the homeostasis
within cells. Subsequently, when these proteases are dysregulated and mislocalized they disrupt
healthy cell dynamics and contribute to many life-threatening pathologies such arteriosclerosis,
osteoporosis and cancer. As such many pharmaceutical companies and research teams are highly
interested in these proteases as targets. One emergent strategy is the spatiotemporal control of
biological processes. In relation to this, a series of spatiotemporally controlled inhibitors of CA
proteases are being developed by the Kodanko Lab. This thesis describes the investigation of two
new cathepsin K (CST-K) inhibitor derivatives and a new RuII-inhibitor binding protocol.
With regards to the free inhibitor derivatives, increased basicity at P2 and P3 decreased the
efficacy of the inhibitors. Also, described herein is the successful caging and photo-release of one
of the dipeptide nitrile inhibitors. The new RuII chaperone ([RuII])–inhibitor binding protocol is
aimed at increasing the stability of RuII-inhibitor complexes in cell growth media. The
investigation has revealed the drawbacks of the new binding protocol. Spatiotemporal control over
protein inhibition was ineffective as a result of the promiscuity of the CST-K active site and the
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terminal and unshielded position of the warhead. It became clear that the warhead of the inhibitor
must be sufficiently hindered when caged to produce a substantial dark/light IC50 ratio (DLIR).
This work is expected to improve the conceptualization of future investigations.
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